Focused On-demand Library for Y+L amino acid transporter 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.







Alternative names:

Monocyte amino acid permease 2; Solute carrier family 7 member 7; y(+)L-type amino acid transporter 1

Alternative UPACC:

Q9UM01; B2RAU0; D3DS26; O95984; Q53XC1; Q86U07; Q9P2V5


Y+L amino acid transporter 1, also known as Solute carrier family 7 member 7, plays a crucial role in the transport of cationic amino acids across cell membranes. It functions as a heterodimer with SLC3A2, facilitating the efflux of cationic amino acids in exchange for neutral amino acids and sodium ions. This process is vital for nitric oxide synthesis and arginine transport in non-polarized cells, such as monocytes, essential for their proper function.

Therapeutic significance:

Y+L amino acid transporter 1's malfunction is linked to Lysinuric Protein Intolerance (LPI), a metabolic disorder characterized by poor nutrient absorption and severe systemic symptoms. Understanding the role of Y+L amino acid transporter 1 could open doors to potential therapeutic strategies for treating LPI, emphasizing the importance of targeted research in this area.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.